G MEDPAR Stock

Equities

GMVDF

KYG394621414

Delayed OTC Markets 09:51:25 2024-04-26 am EDT 5-day change 1st Jan Change
0.02 USD +17.65% Intraday chart for G MEDPAR +5.82% -7.41%
Sales 2023 * 20.4M Sales 2024 * - Capitalization 4.5M
Net income 2023 * -3M Net income 2024 * - EV / Sales 2023 * 0.22 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 84
Yield 2023 *
-
Yield 2024 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
G Medical Innovations Holdings Ltd announced that it has received $0.5 million in funding CI
G Medical Innovations Holdings Ltd announced that it expects to receive $0.5 million in funding CI
G Medical Innovations Holdings Ltd Announces CFO Changes CI
G Medical Innovations Holdings Ltd(OTCPK:GMVD.F) dropped from NASDAQ Composite Index CI
Certain Options of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023. CI
Certain Covertible Debentures of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023. CI
Certain Warrants of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023. CI
Certain Ordinary Shares of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023. CI
Certain Rights of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023. CI
ThinkEquity Initiates G Medical Innovations at Buy Rating With $4 Price Target MT
G Medical Innovations Holdings Ltd Announces Executive Changes CI
Tranche Update on G Medical Innovations Holdings Ltd's Equity Buyback Plan announced on May 20, 2022. CI
Tranche Update on G Medical Innovations Holdings Ltd's Equity Buyback Plan announced on May 20, 2022. CI
G Medical Innovations Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
G Medical Innovations Says Nasdaq's Hearings Panel Grants Request for Continued Listing MT
More news
1 day+17.65%
1 week+5.82%
Current month+63.93%
1 month+98.02%
3 months-20.00%
6 months-29.82%
Current year-7.41%
More quotes
1 week
0.01
Extreme 0.0108
0.02
1 month
0.01
Extreme 0.01
0.02
Current year
0.01
Extreme 0.01
0.04
1 year
0.01
Extreme 0.0061
0.57
3 years
0.01
Extreme 0.0061
235.90
5 years
0.01
Extreme 0.0061
235.90
10 years
0.01
Extreme 0.0061
235.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 14-10-02
Director of Finance/CFO 44 22-07-30
Chief Tech/Sci/R&D Officer 54 17-11-30
Members of the board TitleAgeSince
Chief Executive Officer 73 14-10-02
Chairman 70 14-08-20
Director/Board Member 74 17-02-23
More insiders
Date Price Change Volume
24-04-26 0.02 +17.65% 14 807
24-04-25 0.017 +13.33% 12,536
24-04-23 0.015 -6.25% 24,103
24-04-22 0.016 -15.34% 6,217
24-04-19 0.0189 -5.50% 41,061

Delayed Quote OTC Markets, April 26, 2024 at 09:51 am EDT

More quotes
G Medical Innovations Holdings Ltd. is a mobile health (mHealth) and e-health company. The Company is focused on the development of mHealth and telemedicine solutions and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. Its product lines consist of its Prizma medical device, a clinical grade device that can transform any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Prolongation Syndrome Detection Capabilities Patch. Its monitoring services include the provision of independent diagnostic testing facilities and private monitoring services. It also develops wireless vital signs monitoring systems.
Sector
-
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.017 USD
Average target price
210 USD
Spread / Average Target
+1,235,195.35%
Consensus

Quarterly revenue - Rate of surprise